Regulatory Approvals

The publication emphasizes physician training and professional development, with particular attention to digital innovation.

Alzheimer’s disease drives up to 70% of dementia cases worldwide, presenting healthcare systems with mounting challenges.

The NMPA based its approval decision on Phase III clinical trial data published in The Lancet Diabetes & Endocrinology in June 2025.

NAFDAC released the public alert following a Notice of Concern from the WHO Prequalification service.

Abbott engineered the HERO reader to be 60% lighter than its predecessor, making it practical for daily use and convenient enough for patients to carry during travel.

Developed jointly by the Drugs for Neglected Diseases initiative and Sanofi, Acoziborole Winthrop represents a substantial improvement over existing therapies, which require either a 10-day oral regimen or combined injections and oral medications for advanced cases.

Moscow’s approach recognizes that medical AI does not replace doctors but rather functions as a supportive instrument in the hands of qualified radiologists.

The Lassa Fever E2E Access Roadmap establishes a comprehensive, regionally driven approach that connects every critical stage in transitioning a vaccine from development to sustained, widespread use.

The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.

EU GMP certification confirms that Bioventure Healthcare meets the European Union’s demanding requirements for pharmaceutical manufacturing.